A practical reference on clinical endpoint: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-11. Anything still debated is marked as such rather than presented as settled.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
| Property | Value | Notes |
|---|---|---|
| Storage of dry powder | -20 °C or below | Common practice for long-term retention |
| Storage after reconstitution | 2-8 °C, short term | Solution stability is limited compared with dry powder |
| Typical analytical method | Reversed-phase HPLC | Usually paired with mass spectrometry for mass confirmation |
| Detection wavelength | About 214 nm | Peptide backbone absorbance; buffer background must be controlled |
| Counter-ion forms | Acetate or trifluoroacetate | Affects mass balance and reported concentration |
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
As a mere graduate student, in 1972 Candace Pert discovered the brain’s opiate receptor – the cellular site where the body’s painkillers and "bliss-makers", the endorphins – bond with cells to weave their magic. Pert's discovery led to a revolution in neuroscience, helping open the door to the "information-based" model of the brain which is now replacing the old "structuralist" model... Molecules of Emotion begins as an eye-opener into the intellectual warfare of modern scientific discovery – the gamesmanship, the sly purloining of others' results – but also into the round-the-clock work, the exhilaration of a shared breakthrough, and the slow, painful rise of women in the scientific professions. The book concludes with the author integrating the science she pioneered with the holistic "energy medicines" which work on the same principles – till now without scientific rationales.
The fibroblast-like synoviocytes (derived from mesenchyme) manufacture a long-chain sugar polymer called hyaluronan (hence rich in endoplasmic reticulum); which makes the synovial fluid "ropy"-like egg-white, together with a molecule called lubricin, which lubricates the joint surfaces. The water of synovial fluid is not secreted as such but is effectively trapped in the joint space by the hyaluronan. The macrophage-like synovial cells (derived from monocytes in blood) are responsible for the removal of undesirable substances from the synovial fluid (hence are rich in Golgi apparatus). It accounts for approximately 25% of cells lining the synovium.
In the modern bodybuilding industry, the term "professional" generally means a bodybuilder who has won qualifying competitions as an amateur and has earned a "pro card" from their respective organization. Professionals earn the right to compete in competitions that include monetary prizes. A pro card also prohibits the athlete from competing in federations other than the one from which they have received the pro card. Depending on the level of success, these bodybuilders may receive monetary compensation from sponsors, much like athletes in other sports.
Sources: en.wikipedia.org
=== Research on hemophilia gene therapy === High was a faculty member at the University of North Carolina - Chapel Hill for seven years, where she started her career by cloning the normal canine Factor IX gene and then characterizing the mutation in a naturally occurring canine model of hemophilia B, to enable gene therapy studies for the disease in a canine model. She also identified several mutations responsible for human hemophilia B, as well as Factor VII, and Factor X-deficient blood clotting disorders. High moved to the University of Pennsylvania and Children's Hospital of Philadelphia, where she began pioneering clinical trials of gene therapy for blood disorders. During her career at the University of Pennsylvania, High expanded her research into gene therapy solutions for hereditary blindness together with Dr. Jean Bennett. She was the director of the Center for Cellular and Molecular Therapeutics, and beginning in 2001, head of hematology research, at the Children's Hospital of Philadelphia, where she was also an investigator of the Howard Hughes Medical Institute.
About 86% of molybdenum produced is used in metallurgy, with the rest used in chemical applications. The estimated global use is structural steel 35%, stainless steel 25%, chemicals 14%, tool & high-speed steels 9%, cast iron 6%, molybdenum elemental metal 6%, and superalloys 5%. Molybdenum can withstand extreme temperatures without significantly expanding or softening, making it useful in environments of intense heat, including military armor, aircraft parts, electrical contacts, industrial motors, and supports for filaments in light bulbs. Most high-strength steel alloys (for example, 41xx steels) contain 0.25% to 8% molybdenum. Even in these small portions, more than 43,000 tonnes of molybdenum are used each year in stainless steels, tool steels, cast irons, and high-temperature superalloys. Molybdenum is also used in steel alloys for its high corrosion resistance and weldability. Molybdenum contributes corrosion resistance to type-300 stainless steels (specifically type-316) and especially so in the so-called superaustenitic stainless steels (such as alloy AL-6XN, 254SMO and 1925hMo). Molybdenum increases lattice strain, thus increasing the energy required to dissolve iron atoms from the surface. Molybdenum is also used to enhance the corrosion resistance of ferritic (for example grade 444) and martensitic (for example 1.4122 and 1.4418) stainless steels. Because of its lower density and more stable price, molybdenum is sometimes used in place of tungsten.
== Substrate depletion == In 2022, it was discovered that aminoacyl-tRNA synthetases may incorporate alternative amino acids during shortages of their precursors. In particular, tryptophanyl-tRNA synthetase (WARS1) will incorporate phenylalanine during tryptophan depletion, essentially inducing a W>F codon reassignment. Depletion of the other substrate of aminoacyl-tRNA synthetases, the cognate tRNA, may be relevant to certain diseases, e.g. Charcot–Marie–Tooth disease. It was shown that CMT-mutant glycyl-tRNA synthetase variants are still able to bind tRNAGly but fail to release it, leading to depletion of the cellular pool of glycyl-tRNAGly, what in turn results in stalling of the ribosome on glycine codons during mRNA translation.
=== Controversy of term === There is debate on whether the term "cyber warfare" is accurate. In 2012, Eugene Kaspersky, founder of Kaspersky Lab, concluded that "cyberterrorism" is a more accurate term than "cyberwar." He states that "with today's attacks, you are clueless about who did it or when they will strike again. It's not cyber-war, but cyberterrorism." Howard Schmidt, former Cyber Security Coordinator in the Obama administration, said that "there is no cyberwar... I think that is a terrible metaphor and I think that is a terrible concept. There are no winners in that environment." Some experts take issue with the possible consequences linked to the warfare goal. In 2011, Ron Deibert, of Canada's Citizen Lab, warned of a "militarization of cyberspace", as militaristic responses may not be appropriate. However, to date, even serious cyber-attacks that have disrupted large parts of a nation's electrical grid (230,000 customers, Ukraine, 2015) or affected access to medical care, thus endangering life (UK National Health Service, WannaCry, 2017) have not led to military action. In 2017, Oxford academic Lucas Kello proposed a new term, "Unpeace", to denote highly damaging cyber actions whose non-violent effects do not rise to the level of traditional war. Such actions are neither warlike nor peace-like. Although they are non-violent, and thus not acts of war, their damaging effects on the economy and society may be greater than those of some armed attacks.
Sources: en.wikipedia.org
Democrats had differing views on why Harris lost the election. Vermont Senator Bernie Sanders blamed Democrats for having abandoned the working class. Democratic National Committee chair Jaime Harrison dismissed Sanders' criticism. Former House Speaker Nancy Pelosi also disagreed with Sanders, blaming the party's loss on Biden's late exit and the lack of an open Democratic primary. Senator Chris Murphy (D-CT) believed that the Democrats could not connect to a large number of voters and should embrace populism going forward. Representative Ritchie Torres (D-NY) attributed Trump's victory to public discontent over inflation and immigration; he asserted that Harris ran an effective campaign, but could not overcome a difficult electoral environment.
The Ancient Greek language originally had no word for matter in general, as opposed to raw material suitable for some specific purpose or other, so Aristotle adapted the word for "wood" to this purpose. The idea that everything physical is made of the same basic substance holds up well under modern science, although it may be thought of more in terms of energy or matter/energy. The Latin equivalent of the hyle concept – and later its medieval version – also emerged from Aristotle's notion. The Greek term's Latin equivalent was silva, which literally meant woodland or forest. However, Latin thinkers opted for a word that had a technical sense (rather than literal meaning). This emphasized silva as that of which a thing is made, but one that remained a substratum with changed form. The word materia was chosen instead to indicate a meaning not in handicraft but in the role that mother (mater) plays in conception. Aristotle's concept of hyle is the principle that correlates with shape and this can be demonstrated in the way the philosopher described hyle, saying it is that which receives form or definiteness, that which is formed. It can also be the material cause underlying a change in Aristotelian philosophy. Aristotle explained that "By hyle I mean that which in itself is neither a particular thing nor of a certain quantity nor assigned to any other of the categories by which being is determined." This means that hyle is brought into existence not due to its being its agent or its own actuality but only when form attaches to it.
==== Planulae ==== The time from spawning to larval settlement is usually two to three days but can occur immediately or up to two months. Broadcast-spawned planula larvae develop at the water's surface before descending to seek a hard surface on the benthos to which they can attach and begin a new colony. The larvae often need a biological cue to induce settlement such as specific crustose coralline algae species or microbial biofilms. High failure rates afflict many stages of this process, and even though thousands of eggs are released by each colony, few new colonies form. During settlement, larvae are inhibited by physical barriers such as sediment, as well as chemical (allelopathic) barriers. The larvae metamorphose into a single polyp and eventually develops into a juvenile and then adult by asexual budding and growth.
Sources: en.wikipedia.org
Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.